{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:40:33Z","timestamp":1789479633741,"version":"build-2803163510"},"reference-count":48,"publisher":"Informa UK Limited","issue":"6","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Immunology"],"published-print":{"date-parts":[[2025,6,3]]},"DOI":"10.1080\/1744666x.2025.2512452","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T10:40:13Z","timestamp":1748256013000},"page":"711-721","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Potential future biologic therapies for the treatment of vitiligo: focus on phase 2 and 3"],"prefix":"10.1080","volume":"21","author":[{"given":"Vincenzo","family":"Picone","sequence":"first","affiliation":[{"name":"University of Naples Federico II","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Coronella","sequence":"additional","affiliation":[{"name":"University of Naples Federico II","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Scalvenzi","sequence":"additional","affiliation":[{"name":"University of Naples Federico II","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cataldo","family":"Patruno","sequence":"additional","affiliation":[{"name":"University of Molise","place":["Campobasso, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Lizzi","sequence":"additional","affiliation":[{"name":"University of Naples Federico II","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Cimmino","sequence":"additional","affiliation":[{"name":"University of Naples Federico II","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Napolitano","sequence":"additional","affiliation":[{"name":"University of Naples Federico II","place":["Naples, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1072837"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29307"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10071639"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.03.025"},{"issue":"2","key":"e_1_3_5_7_1","first-page":"797","article-title":"Updates and new medical treatments for vitiligo (review)","volume":"22","author":"Kubelis-L\u00f3pez DE","year":"2021","unstructured":"Kubelis-L\u00f3pez DE, Zapata-Salazar NA, Said-Fern\u00e1ndez SL, et al. Updates and new medical treatments for vitiligo (review). ExpThermed. 2021 Aug;22(2):797. Epub 2021 May 25.","journal-title":"ExpThermed"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/cosmetics10030084"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19162"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512152"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-100919-023531"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2013.10.010"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01604-z"},{"key":"e_1_3_5_14_1","article-title":"Use of Anifrolumab in systemic lupus erythematosus, cutaneous lupus erythematosus, and other autoimmune dermatoses","author":"Mart\u00edn-Torregrosa D","year":"2024","unstructured":"Mart\u00edn-Torregrosa D, Mansilla-Polo M, Morgado-Carrasco D. Use of Anifrolumab in systemic lupus erythematosus, cutaneous lupus erythematosus, and other autoimmune dermatoses. ActasDermosifiliogr. 2024;116(1):T55\u2013T67.","journal-title":"ActasDermosifiliogr"},{"key":"e_1_3_5_15_1","unstructured":"Efficacy and tolerance of the association of ANIFROLUMAB (300mg) IV every four weeks and phototherapy versus phototherapy in adults with progressive vitiligo (NCT05917561)."},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790125"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2023.2285011"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20411"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-023-00151-1"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2023.12.008"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.10.034"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24087185"},{"key":"e_1_3_5_23_1","unstructured":"A study to evaluate the efficacy and safety of INCB054707 in participants with vitiligo (NCT04818346)."},{"key":"e_1_3_5_24_1","unstructured":"A study to evaluate efficacy and safety of Povorcitinib in participants with nonsegmental vitiligo (STOP-V1) (NCT06113445)."},{"key":"e_1_3_5_25_1","unstructured":"A study to evaluate efficacy and safety of Povorcitinib in participants with nonsegmental vitiligo (STOP-V2) (NCT06113471)."},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llae309"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-023-01336-w"},{"key":"e_1_3_5_28_1","unstructured":"A study to evaluate adverse events and change in disease activity with oral tablets of Upadacitinib in adult participants with non-segmental vitiligo (NCT04927975)."},{"key":"e_1_3_5_29_1","unstructured":"A study to assess adverse events and effectiveness of upadacitinib oral tablets in adult and adolescent participants with vitiligo (viti-up) (NCT06118411)."},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.9b00188"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.09.021"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S334727"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.15177"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17157"},{"key":"e_1_3_5_35_1","unstructured":"A 52-week study of ritlecitinib oral capsules in adults and adolescents with nonsegmental vitiligo (active and stable) tranquillo (NCT05583526)."},{"key":"e_1_3_5_36_1","unstructured":"A 52-week study to learn about the safety and effects of Ritlecitinib in participants with nonsegmental vitiligo (tranquillo LTE) (NCT06163326)."},{"key":"e_1_3_5_37_1","unstructured":"A 104-week study of ritlecitinib oral capsules in adults with nonsegmental vitiligo (active and stable) tranquillo 2 (NCT06072183)."},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1163"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42519"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21826"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/eeglsa"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-024-02522-3"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.4724"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00105-024-05312-z"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118828"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2018.10.421"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2020.108670"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1159\/000528180"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.8117"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.11.012"}],"container-title":["Expert Review of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/1744666X.2025.2512452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T09:22:59Z","timestamp":1750238579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/1744666X.2025.2512452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,3]]}},"alternative-id":["10.1080\/1744666X.2025.2512452"],"URL":"https:\/\/doi.org\/10.1080\/1744666x.2025.2512452","relation":{},"ISSN":["1744-666X","1744-8409"],"issn-type":[{"value":"1744-666X","type":"print"},{"value":"1744-8409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-02-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}